Janux Therapeutics (JANX) Cash from Investing Activities (2021 - 2026)

Janux Therapeutics (JANX) has reported Cash from Investing Activities for 6 consecutive years, with $8.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Investing Activities rose 102.43% year-over-year to $8.3 million; the TTM figure through Mar 2026 stood at $47.7 million (up 109.84% YoY), while the FY2025 annual figure was -$301.0 million, down 16.65% from the prior year.
• Cash from Investing Activities slipped to $8.3 million in Q1 2026 per JANX's latest filing, from $29.5 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $33.9 million in Q4 2024 and bottomed at -$340.4 million in Q1 2025.
• Historically, Cash from Investing Activities has averaged -$31.4 million across 5 years, with a median of $8.3 million in 2025.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities soared 20405.88% — and 2024, when it plunged 1201.33%.
• Janux Therapeutics' Cash from Investing Activities stood at -$1.6 million in 2022, then jumped by 793.45% to $11.1 million in 2023, then surged by 205.01% to $33.9 million in 2024, then decreased by 12.92% to $29.5 million in 2025, then plunged by 71.95% to $8.3 million in 2026.
• Business Quant data shows JANX's Cash from Investing Activities at $8.3 million in Q1 2026, $29.5 million in Q4 2025, and $8.3 million in Q3 2025.